Home / Publication / Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

論文

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Author(s): John Gibbs, Sameer Doshi, Mita Kuchimanchi, Anita Grover, Maurice Emery, Michael Dodds, Megan Gibbs, Ransi Somaratne, Scott Wasserman, Dirk Blom

Year: 2016年11月15日

AUC（線形および対数線形）の計算

ブログ

Accumulation: What It Means and How to Calculate It

ブログ

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

ビデオ

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

ビデオ

Powered by Translations.com GlobalLink Web Software

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

AUC（線形および対数線形）の計算

Accumulation: What It Means and How to Calculate It

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

メルマガ登録

クイックアクセス

ソリューション

お問合せ